Your guide to Biotech billions
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Wall Street Fundamentals.
| Novel Breakthrough Is The Secret to This Biotech |
| 
How did it happen? Easy. Grail invented a new way of screening for cancer drugs with gene sequencing. Shortly after, they sold to Illumina for a staging $8 BILLION. Now, almost the exact same thing is happening again. One company that has smart investors chomping at the bit. A company who has a patent pending with the FDA, for a new investigation that has the potential to change medical drug delivery forever. >>See 2024's Top Biotech Investment? Regards,
Wall Street Fundamentals | |
|
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of Tharimmune Inc. (NASDAQ: THAR). The compensation consists of up to $2,000 and was received/will be received from Investing Media Solutions. This compensation should not be considered as an endorsement of the securities of adviser harimmune Inc. (NASDAQ: THAR) and we are not responsible for any errors or omissions in any information provided about the securities of harimmune Inc. (NASDAQ: THAR) by Wall Street Fundamentals. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 9/26/24. Behind the Markets
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
Unsubscribeinvisiblelink
|
|
No comments:
Post a Comment